Anti-Mouse CD123 FITC 500 ug
- Known as:
- Antibody toMouse CD123 fluorecein 500 ug
- Catalog number:
- 11-1231-85
- Category:
- -
- Supplier:
- eBioscience
- Gene target:
- Anti-Mouse CD123 FITC 500
Ask about this productRelated genes to: Anti-Mouse CD123 FITC 500 ug
- Gene:
- IL3RA NIH gene
- Name:
- interleukin 3 receptor subunit alpha
- Previous symbol:
- -
- Synonyms:
- CD123
- Chromosome:
- Xp22.3 and Yp13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-10-28
- Date modifiied:
- 2015-12-11
Related products to: Anti-Mouse CD123 FITC 500 ug
Related articles to: Anti-Mouse CD123 FITC 500 ug
- Plasmacytoid dendritic cells (pDCs) have been implicated in both restraining and promoting intrahepatic cholangiocarcinoma (iCCA), leaving their clinical relevance and therapeutic potential unresolved. - Source: PubMed
Publication date: 2026/07/28
Chen Mei-RuXie Xiao-LiZhou Yan-LiTian Jin-MeiZhao YingHou SupingWang Yuan-YuanLu Ji-ChaoZhao Dong-QiangCui Zhao-BoZhang Li-Xian - Patients with relapsed acute myeloid leukemia (AML), particularly following allogeneic stem cell transplant (alloHCT), have extremely limited therapeutic options. CD123 is an AML-associated antigen and represents an attractive target for immunotherapy. We report outcomes of a phase 1 trial evaluating CD123-targeting chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory (r/r) AML or blastic plasmacytoid dendritic cell neoplasm (BPDCN). - Source: PubMed
Publication date: 2026/08/07
Budde Lihua EDel Real Marissa MSong JooStiller TraceyWang YanAribi AhmedSandhu KaramjeetNakamura RyotaroMarcucci Emanuela CWu Jian JNg KennethClark Mary CWood BrentWagner Jamie RPaul JinnyBrown Christine EStein AnthonyMarcucci GuidoBlanchard M SuzettePalmer JoycelynneForman Stephen J - Chimeric antigen receptor (CAR) T cells require an extracellular targeting domain for antigen specificity, typically an scFv. VHH antibodies are emerging as alternative CAR binding regions due to their reduced size, improved stability, and CDR3 loop architecture. Herein, we generated and compared VHH and scFv antibodies targeting CD123, via immunized phage display libraries, selecting ten antibody pairs based on comparable domain targeting and kinetic profiles (K range M 10-10). The VHH antibody fragments showed improved stability (Tm Δ7.85°C), reduced aggregation, and a favorable surface charge. CARs incorporating a VHH demonstrated higher IL2 and IFNγ secretion than scFv-derived CARs during in vitro analysis and substantially enhanced survival and decreased tumor burden in a xenograft murine model of acute myeloid leukemia (AML). This comprehensive comparison of the two most adopted antibody classes provides a rationale for the selection of VHH as preferred CAR binding domains. - Source: PubMed
Publication date: 2026/06/10
Kinna AlexanderDatta PreetaBughda ReyisaParekh FarhaanRobson MathewJha RamWu PhillipScott IanHogben ElizabethAmin OliverWeng-Kit Cheung GordonHazelton WarrenAkbar ZulaikhaLamb KatarinaMacken EmilyAllen ChrisPanovska SofiHogan LisaEl-Kholy MohamedShrestha ReeveshPopplewell JonathanKokalaki EvangeliaSillibourne JamesThomas SimonOnuoha ShimobiFerrari MathieuPule Martin - Acute myeloid leukemia is a hematological malignancy characterized by clonal expansion and blockade of myeloid precursor differentiation. This results in poor survival rates, particularly among older patients and those with refractory disease. CD123, the α-chain of the interleukin-3 receptor, is overexpressed in leukemic stem cells and represents a promising therapeutic target. - Source: PubMed
Publication date: 2026/06/11
Vito Vitória MariaBoff Vinícius AndréDemarchi Izabel Galhardode Moraes Ana Carolina Rabello - Rosacea, discoid lupus erythematosus (DLE), and polymorphous light eruption (PLE) can present with overlapping clinical and histopathological features. This study aimed to compare the immunohistochemical and histopathological findings of these lesions and to evaluate the contribution of immunohistochemistry to the differential diagnosis. - Source: PubMed
Publication date: 2026/04/27
Aydin OzgeKilinc Fahriye